Abstract
Tamoxifen (ICI 46474) was given by mouth to patients with advanced, recurrent, or metastatic breast carcinoma. At a dosage of 10 mg twice daily 60% of patients showed arrest or reversal of tumour growth. At a dosage of 20 mg twice daily 77% showed arrest or reversal of tumour growth. Side effects were usually trivial and their incidence was the same at both dose levels. No patients showed virilization of fluid retention.
Full text
PDF

Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- HERBST A. L., GRIFFITHS C. T., KISTNER R. W. CLOMIPHENE CITRATE (NSC-35770) IN DISSEMINATED MAMMARY CARCINOMA. Cancer Chemother Rep. 1964 Dec;43:39–41. [PubMed] [Google Scholar]
- KISTNER R. W., SMITH O. W. Observations on the use of a non-steroidal estrogen antagonist: MER-25. Surg Forum. 1960;10:725–729. [PubMed] [Google Scholar]